Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global…
Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Paris, March 5, 2026. The Board of Directors of Sanofi has…
Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that…
Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and…
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public…
Männedorf, Switzerland, February 10, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media Conference…
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy…
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on…
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period…
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund…